Share capital and premium related to the share capitals

6 Months Ended

Jun. 30, 2023

Share capital and premium related to the share capitals

Note 15. Share capital and premium related to the share capitals


Nature of the Transactions	Share Capital		Share premium			Number of shares		Nominal value
	$ in thousands (except number of shares)							in $
Balance as of January 1, 2022		2,945		934,696			45,484,310	0.05
Exercise of share warrants, employee warrants and stock options		1		—			26,500		—
Non-cash stock-based compensation expense		—		5,331			—		—
Other movements		—		(372,744	)		—		—
Balance as of June 30, 2022		2,946		567,284			45,510,810	0.05
Balance as of January 1, 2023		2,955		583,122			45,675,968	0.05
Non-cash stock-based compensation expense		—		4,053			—		—
Capital increase of Cellectis (1)		536		24,482			9,907,800
Transaction costs related to Cellectis’ capital increase (2)		—		(1,455	)		—		—
Other movements		—		(133,976	)		—		—
Balance as of June 30, 2023		3,491		476,224			55,583,768	0.05

Capital evolution during the six-month period ended June 30, 2023

(1)

During the six-month period ended June 30, 2023, 9,907,800 shares were issued in the Cellectis Follow-on Offering with gross proceeds of $24.8 million.

(2)

These costs correspond to the issuance costs incurred in 2023 in connection with the Cellectis Follow-on Offering as a reduction of share premium, in addition to the $0.6 million costs incurred and deducted from Equity in the fourth quarter of 2022. The total transaction costs for this Cellectis Follow-on Offering amount to $2.0 million.

(3)

During the annual shareholders meeting of June 27, 2023, the shareholders, in accordance with French Law, approved the absorption of $134.0 million of retain²ed earnings into share premium. This transaction has no impact on the total equity, comprehensive income (loss), assets (including cash) nor liabilities.